Fabrazyme and Nosebleed - a phase IV clinical study of FDA data

Summary:

Nosebleed is reported as a side effect among people who take Fabrazyme (agalsidase beta), especially for people who are male, 50-59 old, have been taking the drug for 1 - 2 years also take Aspirin, and have Fabry's disease.

The phase IV clinical study analyzes which people have Nosebleed when taking Fabrazyme. It is created by eHealthMe based on reports of 10,390 people who have side effects when taking Fabrazyme from the FDA, and is updated regularly.

What is Fabrazyme?

Fabrazyme has active ingredients of agalsidase beta. eHealthMe is studying from 10,406 Fabrazyme users. Check the latest studies of Fabrazyme.

What is Nosebleed?

Nosebleed (bleeding from nose) is found to be associated with 2,080 drugs and 3,091 conditions by eHealthMe. Check the latest studies of Nosebleed.

On Jul, 14, 2026

10,390 people reported to have side effects when taking Fabrazyme.
Among them, 18 people (0.17%) have Nosebleed.

Among these 18 people:

How long have people been on Fabrazyme when they have Nosebleed? *

What is the gender of people who have Nosebleed when taking Fabrazyme? *

female: 12.5 %
male: 87.5 %

What is the age of people who have Nosebleed when taking Fabrazyme? *

What are other drugs people take besides Fabrazyme? *

What are other side effects people have besides Nosebleed? *

Fatigue (feeling of tiredness): 6 people, 33.33%
Drowsiness: 6 people, 33.33%
Feeling Abnormal: 6 people, 33.33%
Scab (a hard coating on the skin formed during the wound healing): 5 people, 27.78%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 5 people, 27.78%
Skin Disorder (skin disease): 5 people, 27.78%
Neck Pain: 4 people, 22.22%
Hyperthyroidism (over activity of the thyroid gland): 4 people, 22.22%
Nausea And Vomiting: 4 people, 22.22%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 4 people, 22.22%

What are the existing conditions these people have? *

Fabry's Disease (build up of a particular type of fat, called globotriaosylceramide, in the body's cells): 11 people, 61.11%
Embolism (obstruction of an artery, typically by a clot of blood or an air bubble): 2 people, 11.11%
Pain: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Fabrazyme and have Nosebleed?

- Check whether Nosebleed is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fabrazyme:

Fabrazyme (10,406 reports)

Nosebleed treatments and more:

Nosebleed (92,075 reports)

Browse all side effects of Fabrazyme:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nosebleed:

Nosebleed (2,080 drugs)

Browse all the conditions that are associated with Nosebleed:

Nosebleed (3,091 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on agalsidase beta (the active ingredients of Fabrazyme) and Fabrazyme (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.